| HOME >> BIOLOGY >> TECHNOLOGY |
BETHESDA, Md., Sept. 26 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammation and autoimmune diseases, today announced that Dr. Christian Itin, President and Chief Executive Officer of Micromet, will present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum in Zurich, Switzerland on Tuesday, October 2, 2007 at 12:00 noon central European time (6:00 am Eastern time).
About Micromet, Inc. (http://www.micromet-inc.com)
Micromet, Inc. is a biopharmaceutical company focusing on the
development of novel, proprietary antibody-based products for cancer,
inflammation and autoimmune diseases. Three product candidates are
currently in clinical trials. MT103, also known as MEDI-538, is the first
product candidate based on Micromet's novel BiTE(R) antibody product
development platform and is being evaluated in a phase 1 clinical trial for
the treatment of patients with non- Hodgkin's lymphoma. The BiTE antibody
product development platform is based on a unique, antibody-based class of
drugs that leverages the cytotoxic potential of T cells in the treatment of
cancer. T cells are the most powerful 'killer cells' of the human immune
system. Micromet has established a collaboration with MedImmune, Inc. for
MT103/MEDI-538. The second clinical stage product candidate is
adecatumumab, also known as MT201, a recombinant human monoclonal antibody
which targets EpCAM expressing tumors. Adecatumumab is being developed for
the treatment of patients with breast cancer. A phase 2a clinical trial in
this indication has been complete
'/>"/>
| SOURCE Micromet, Inc. Copyright©2007 PR Newswire. All rights reserved |